New combo shows promise for tough hodgkin lymphoma cases
NCT ID NCT02227199
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tested a new combination of drugs for people with Hodgkin lymphoma that either returned after treatment or didn't respond. The goal was to find the safest dose of a targeted drug (brentuximab vedotin) when added to standard chemotherapy. 45 adults took part, and the study looked at side effects and how many achieved complete remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer transplant study tests safer GVHD prevention
- Can a weekly drug combo outsmart resistant lymphoma?
- Immunotherapy combo aims to stop hodgkin lymphoma relapse after transplant
- Stem cell transplant study seeks best way to prevent immune attack
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New combo therapy aims to outsmart tough hodgkin lymphoma